An agreement between Taisho Pharmaceutical Co Ltd. and Takeda Pharmaceutical Co Ltd. on the distribution of Biofermin Pharmaceutical Co Ltd.'s OTC drugs and quasi-drugs will terminate on 30 September. Under the new agreement, Taisho will undertake direct distribution activities with respect to the OTC drug and quasi-drug transactions from October 2017 onward. Takeda will continue to distribute domestic prescription drugs as it did before.

Taisho will work to further solidify Biofermin's position as the top brand in Japan's intestinal regulator field by directly distributing Biofermin products while also working to maximise the value of the Biofermin brand through the implementation of measures that take full advantage of its brand power, including strengthening the product lineup.